A novel gene delivery platform based on a commensal human anellovirus demonstrates transduction in multiple tissue types
Brief intro:
- Author: Cato Prince, George Bounoutas, Bolu Zhou, Waseem Raja, Isabella Gold, Riana Pozsgai, Parmi Thakker, Nicole Boisvert, Christopher Reardon, Stephanie Thurmond, Erin Ozturk, Rajendra Boggavarapu, Jenna Antonucci Johnson, Patricio Jeraldo, Simeon Springer, Lovepreet Chahal, Emily Stead, Cameron Dodier, Bryan Vought, Maciej Nogalski, Dhananjay Nawandar, Christopher Wright, Ashley Mackey, Geoffrey Parsons, Joseph Cabral
- Journal: Molecular Therapy
- Doi: https://www.doi.org/10.1016/j.omtm.2025.101597
- Publication Date: 2025/12/11
Abstract
Anelloviridae is a family of non-enveloped viruses with negative-sense, circular, single-stranded DNA genomes that infect vertebrates and are a ubiquitous component of the human virome. The non-pathogenic and commensal nature of anelloviruses makes them compelling candidates as vectors for next-generation genetic medicines. Here we report development of a gene delivery vector system based on an anellovirus of the Betatorquevirus genus. Production is enabled by the development of the self-amplifying trans-complementation of a universal recombinant Anellovector (SATURN) system, which relies on a self-replicating plasmid to provide viral proteins in trans and a Cre-lox-based recombination mechanism to generate single unit-sized circular genomes inside the MOLT-4 production cell line. We demonstrate that the SATURN system can package a vector genome from a single Betatorquevirus with capsids from multiple Betatorquevirus species, supporting the feasibility of establishing a vector platform that takes advantage of anellovirus diversity. The vector demonstrated long-term in vivo function in the mouse eye for 12 months post subretinal administration. Comparable gene expression was achieved to dose-matched adeno-associated virus 9 in vitro and in vivo when transducing HEK293TT cells and the murine brain, respectively. To our knowledge, this is the first report of a functional anellovirus-based gene expression vector.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.